For informational purposes only. Not financial advice, not a recommendation to buy or sell any security. Standing Order is a directory and research project, not an advisory service.
Thesis
Isomorphic Labs is the DeepMind drug-discovery spin-out built around AlphaFold-class structural models and a broader computational pipeline aimed at small-molecule and biologic design. Pharma partnerships with Novartis and Eli Lilly validate the platform commercially while internal programs build optionality.
The bet is that frontier ML on protein structure and interaction prediction collapses early discovery timelines — Isomorphic is the cleanest private exposure to that thesis.
Catalysts
- First wholly-owned programs entering the clinic
- Expansion or extension of Novartis and Lilly collaborations
- New flagship pharma partnerships at attractive economics
- Eventual IPO as a category-defining AI-bio platform